Cargando…

Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic

OBJECTIVES: The COVID‐19 pandemic bears the risk of delayed cancer diagnoses. METHODS: Study on the diagnostic pathway of sinonasal malignancies during the COVID‐19 pandemic. RESULTS: Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartil...

Descripción completa

Detalles Bibliográficos
Autores principales: Meerwein, Christian M., Stadler, Thomas M., Balermpas, Panagiotis, Soyka, Michael B., Holzmann, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513453/
https://www.ncbi.nlm.nih.gov/pubmed/34667832
http://dx.doi.org/10.1002/lio2.640
_version_ 1784583216150085632
author Meerwein, Christian M.
Stadler, Thomas M.
Balermpas, Panagiotis
Soyka, Michael B.
Holzmann, David
author_facet Meerwein, Christian M.
Stadler, Thomas M.
Balermpas, Panagiotis
Soyka, Michael B.
Holzmann, David
author_sort Meerwein, Christian M.
collection PubMed
description OBJECTIVES: The COVID‐19 pandemic bears the risk of delayed cancer diagnoses. METHODS: Study on the diagnostic pathway of sinonasal malignancies during the COVID‐19 pandemic. RESULTS: Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartile range [IQR] 104‐193) vs 139 days (IQR 103‐219) (P = .60). Median time from first appointment at our institution to treatment initiation was even reduced in 2020: 18 days (IQR 11‐25) vs 11 days (IQR 7‐17) (P = .02). A trend toward advanced tumor stages during the pandemic was seen: 11/30 patients (36.7%) ≥ stage 4 in 2018 to 2019 vs 12/19 patients (63.2%) ≥ stage 4 in 2020 (P = .064). CONCLUSION: Both, time to diagnosis and time to treatment initiation were similar during the pandemic. However, a higher proportion of advanced tumors stages was observed. Despite the pandemic, we provided a swift diagnostic workflow, including a virtual tumor board decision and a prompt treatment initiation. Level of Evidence: 4.
format Online
Article
Text
id pubmed-8513453
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-85134532021-10-18 Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic Meerwein, Christian M. Stadler, Thomas M. Balermpas, Panagiotis Soyka, Michael B. Holzmann, David Laryngoscope Investig Otolaryngol Allergy, Rhinology, and Immunology OBJECTIVES: The COVID‐19 pandemic bears the risk of delayed cancer diagnoses. METHODS: Study on the diagnostic pathway of sinonasal malignancies during the COVID‐19 pandemic. RESULTS: Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartile range [IQR] 104‐193) vs 139 days (IQR 103‐219) (P = .60). Median time from first appointment at our institution to treatment initiation was even reduced in 2020: 18 days (IQR 11‐25) vs 11 days (IQR 7‐17) (P = .02). A trend toward advanced tumor stages during the pandemic was seen: 11/30 patients (36.7%) ≥ stage 4 in 2018 to 2019 vs 12/19 patients (63.2%) ≥ stage 4 in 2020 (P = .064). CONCLUSION: Both, time to diagnosis and time to treatment initiation were similar during the pandemic. However, a higher proportion of advanced tumors stages was observed. Despite the pandemic, we provided a swift diagnostic workflow, including a virtual tumor board decision and a prompt treatment initiation. Level of Evidence: 4. John Wiley & Sons, Inc. 2021-09-04 /pmc/articles/PMC8513453/ /pubmed/34667832 http://dx.doi.org/10.1002/lio2.640 Text en © 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Allergy, Rhinology, and Immunology
Meerwein, Christian M.
Stadler, Thomas M.
Balermpas, Panagiotis
Soyka, Michael B.
Holzmann, David
Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic
title Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic
title_full Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic
title_fullStr Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic
title_full_unstemmed Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic
title_short Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic
title_sort diagnostic pathway and stage migration of sinonasal malignancies in the era of the covid‐19 pandemic
topic Allergy, Rhinology, and Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513453/
https://www.ncbi.nlm.nih.gov/pubmed/34667832
http://dx.doi.org/10.1002/lio2.640
work_keys_str_mv AT meerweinchristianm diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic
AT stadlerthomasm diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic
AT balermpaspanagiotis diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic
AT soykamichaelb diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic
AT holzmanndavid diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic